{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:32:58Z","timestamp":1792783978755,"version":"4.5.0"},"reference-count":83,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,11,20]],"date-time":"2015-11-20T00:00:00Z","timestamp":1447977600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Eisai Inc"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","cancertreatmentreviews.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1016\/j.ctrv.2015.11.003","type":"journal-article","created":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T22:18:10Z","timestamp":1449008290000},"page":"47-55","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":181,"special_numbering":"C","title":["Lenvatinib: Role in thyroid cancer and other solid tumors"],"prefix":"10.1016","volume":"42","author":[{"given":"Maria E.","family":"Cabanillas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mouhammed Amir","family":"Habra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ctrv.2015.11.003_b0005","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3322\/caac.21208","article-title":"Cancer Statistics, 2014","volume":"64","author":"Siegel","year":"2014","journal-title":"CA Cancer J Clin"},{"issue":"11","key":"10.1016\/j.ctrv.2015.11.003_b0010","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.6004\/jnccn.2010.0093","article-title":"Thyroid carcinoma","volume":"8","author":"Tuttle","year":"2010","journal-title":"J Natl Compr Canc Netw"},{"issue":"5","key":"10.1016\/j.ctrv.2015.11.003_b0015","doi-asserted-by":"crossref","first-page":"532","DOI":"10.6004\/jnccn.2010.0041","article-title":"The role of radiation therapy in the treatment of medullary thyroid cancer","volume":"8","author":"Terezakis","year":"2010","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.ctrv.2015.11.003_b0020","doi-asserted-by":"crossref","first-page":"803171","DOI":"10.1155\/2013\/803171","article-title":"Cellular signaling pathway alterations and potential targeted therapies for medullary thyroid carcinoma","volume":"2013","author":"Giunti","year":"2013","journal-title":"Int J Endocrinol"},{"key":"10.1016\/j.ctrv.2015.11.003_b0025","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) thyroid carcinoma. Version 2.2015. 2015."},{"issue":"8","key":"10.1016\/j.ctrv.2015.11.003_b0030","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1210\/jc.2005-2838","article-title":"Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy","volume":"91","author":"Durante","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.ctrv.2015.11.003_b0035","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1089\/thy.2012.0520","article-title":"Clinical, safety, and economic evidence in radioactive iodine-refractory differentiated thyroid cancer: a systematic literature review","volume":"23","author":"Anderson","year":"2013","journal-title":"Thyroid"},{"issue":"10","key":"10.1016\/j.ctrv.2015.11.003_b0040","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1007\/s00259-008-0883-1","article-title":"Guidelines for radioiodine therapy of differentiated thyroid cancer","volume":"35","author":"Luster","year":"2008","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"Suppl. 15","key":"10.1016\/j.ctrv.2015.11.003_b0045","article-title":"A phase II trial of the multitargeted kinase inhibitor E7080 in advanced radioiodine (RAI)-refractory differentiated thyroid cancer (DTC) [abstract]","volume":"29","author":"Sherman","year":"2011","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.ctrv.2015.11.003_b0050","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1586\/era.12.96","article-title":"Regional approaches to the management of patients with advanced, radioactive iodine-refractory differentiated thyroid carcinoma","volume":"12","author":"Brose","year":"2012","journal-title":"Expert Rev Anticancer Ther"},{"issue":"11","key":"10.1016\/j.ctrv.2015.11.003_b0055","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1089\/thy.2009.0110","article-title":"Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer","volume":"19","author":"Cooper","year":"2009","journal-title":"Thyroid"},{"issue":"6","key":"10.1016\/j.ctrv.2015.11.003_b0060","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1089\/thy.2008.0403","article-title":"Medullary thyroid cancer: management guidelines of the American Thyroid Association","volume":"19","author":"Kloos","year":"2009","journal-title":"Thyroid"},{"issue":"4","key":"10.1016\/j.ctrv.2015.11.003_b0065","first-page":"335","article-title":"Optimizing therapy for radioactive iodine-refractory differentiated thyroid cancer: current state of the art and future directions","volume":"37","author":"Dadu","year":"2012","journal-title":"Minerva Endocrinol"},{"issue":"3","key":"10.1016\/j.ctrv.2015.11.003_b0070","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.cell.2014.09.050","article-title":"Integrated genomic characterization of papillary thyroid carcinoma","volume":"159","author":"Cancer Genome Atlas Research Network","year":"2014","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.ctrv.2015.11.003_b0075","doi-asserted-by":"crossref","first-page":"R235","DOI":"10.1530\/ERC-15-0070","article-title":"RAS proto-oncogene in medullary thyroid carcinoma","volume":"22","author":"Moura","year":"2015","journal-title":"Endocr Relat Cancer"},{"issue":"11","key":"10.1016\/j.ctrv.2015.11.003_b0080","doi-asserted-by":"crossref","first-page":"4885","DOI":"10.1158\/0008-5472.CAN-09-0727","article-title":"Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1","volume":"69","author":"Ricarte-Filho","year":"2009","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.ctrv.2015.11.003_b0085","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1158\/1078-0432.CCR-06-1125","article-title":"Genetic alterations and their relationship in the phosphatidylinositol 3-kinase\/Akt pathway in thyroid cancer","volume":"13","author":"Hou","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.ctrv.2015.11.003_b0090","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1210\/er.2012-1038","article-title":"Evolving approaches to patients with advanced differentiated thyroid cancer","volume":"34","author":"Haugen","year":"2013","journal-title":"Endocr Rev"},{"issue":"8","key":"10.1016\/j.ctrv.2015.11.003_b0095","doi-asserted-by":"crossref","first-page":"3106","DOI":"10.1210\/jc.2008-0273","article-title":"Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase\/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers","volume":"93","author":"Liu","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.ctrv.2015.11.003_b0100","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1385\/EP:11:1:19","article-title":"Expression of hepatocyte growth factor (HGF) and its receptor (MET) in medullary carcinoma of the thyroid","volume":"11","author":"Papotti","year":"2000","journal-title":"Endocr Pathol"},{"issue":"3","key":"10.1016\/j.ctrv.2015.11.003_b0105","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1158\/1078-0432.1336.11.3","article-title":"Dual inhibition of RET and FGFR4 restrains medullary thyroid cancer cell growth","volume":"11","author":"Ezzat","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.ctrv.2015.11.003_b0110","doi-asserted-by":"crossref","first-page":"2840","DOI":"10.1210\/jc.2006-2707","article-title":"BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism","volume":"92","author":"Durante","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"issue":"18","key":"10.1016\/j.ctrv.2015.11.003_b0115","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1200\/JCO.2008.20.1426","article-title":"BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer","volume":"27","author":"Xing","year":"2009","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2015.11.003_b0120","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/cncr.22754","article-title":"Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroid: a meta-analysis","volume":"110","author":"Lee","year":"2007","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.ctrv.2015.11.003_b0125","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1210\/jc.2011-3106","article-title":"A high percentage of BRAFV600E alleles in papillary thyroid carcinoma predicts a poorer outcome","volume":"97","author":"Guerra","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"10.1016\/j.ctrv.2015.11.003_b0130","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1089\/thy.2007.0357","article-title":"Potent inhibition of thyroid cancer cells by the MEK inhibitor PD0325901 and its potentiation by suppression of the PI3K and NF-\u03baB pathways","volume":"18","author":"Liu","year":"2008","journal-title":"Thyroid"},{"issue":"12","key":"10.1016\/j.ctrv.2015.11.003_b0135","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.1002\/ijc.25304","article-title":"BRAF mutation-selective inhibition of thyroid cancer cells by the novel MEK inhibitor RDEA119 and genetic-potentiated synergism with the mTOR inhibitor temsirolimus","volume":"127","author":"Liu","year":"2010","journal-title":"Int J Cancer"},{"issue":"4","key":"10.1016\/j.ctrv.2015.11.003_b0140","doi-asserted-by":"crossref","first-page":"E577","DOI":"10.1210\/jc.2010-2644","article-title":"The Akt-specific inhibitor MK2206 selectively inhibits thyroid cancer cells harboring mutations that can activate the PI3K\/Akt pathway","volume":"96","author":"Liu","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"29","key":"10.1016\/j.ctrv.2015.11.003_b0145","doi-asserted-by":"crossref","first-page":"26969","DOI":"10.1074\/jbc.M103213200","article-title":"Vascular permeability factor (VPF)\/vascular endothelial growth factor (VEGF) peceptor-1 down-modulates VPF\/VEGF receptor-2-mediated endothelial cell proliferation, but not migration, through phosphatidylinositol 3-kinase-dependent pathways","volume":"276","author":"Zeng","year":"2001","journal-title":"J Biol Chem"},{"issue":"16","key":"10.1016\/j.ctrv.2015.11.003_b0150","first-page":"4645","article-title":"ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration","volume":"62","author":"Wedge","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2015.11.003_b0155","doi-asserted-by":"crossref","first-page":"638747","DOI":"10.1155\/2014\/638747","article-title":"Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models","volume":"2014","author":"Tohyama","year":"2014","journal-title":"J Thyroid Res"},{"issue":"24","key":"10.1016\/j.ctrv.2015.11.003_b0160","first-page":"7284","article-title":"ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases","volume":"62","author":"Carlomagno","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2015.11.003_b0165","unstructured":"CAPRELSA\u00ae (vandetanib). Wilmington, DE: AstraZeneca Pharmaceuticals LP; March, 2014."},{"issue":"9940","key":"10.1016\/j.ctrv.2015.11.003_b0170","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0140-6736(14)60421-9","article-title":"Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial","volume":"384","author":"Brose","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2015.11.003_b0175","unstructured":"COMETRIQ\u00ae (cabozantinib) [summary of product characteristics]. Hampshire, UK: TMC Pharma Services, Ltd; March 26, 2014."},{"key":"10.1016\/j.ctrv.2015.11.003_b0180","unstructured":"LENVIMA\u2122 (lenvatinib) [prescribing infomation]. Woodcliff Lake, NJ: Eisai, Inc.; February, 2015."},{"issue":"1","key":"10.1016\/j.ctrv.2015.11.003_b0185","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.critrevonc.2014.08.007","article-title":"The evolving field of kinase inhibitors in thyroid cancer","volume":"93","author":"Marotta","year":"2015","journal-title":"Crit Rev Oncol Hematol"},{"issue":"2","key":"10.1016\/j.ctrv.2015.11.003_b0190","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1200\/JCO.2011.35.5040","article-title":"Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial","volume":"30","author":"Wells","year":"2012","journal-title":"J Clin Oncol"},{"issue":"29","key":"10.1016\/j.ctrv.2015.11.003_b0195","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1200\/JCO.2012.48.4659","article-title":"Cabozantinib in progressive medullary thyroid cancer","volume":"31","author":"Elisei","year":"2013","journal-title":"J Clin Oncol"},{"issue":"15 Suppl.","key":"10.1016\/j.ctrv.2015.11.003_b0200","article-title":"Efficacy of cabozantinib (Cabo) in medullary thyroid cancer (MTC) patients with RAS or RET mutations: Results from a phase III study [abstract]","volume":"31","author":"Sherman","year":"2013","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.ctrv.2015.11.003_b0205","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1406470","article-title":"Lenvatinib versus placebo in radioiodine-refractory thyroid cancer","volume":"372","author":"Schlumberger","year":"2015","journal-title":"N Engl J Med"},{"issue":"29","key":"10.1016\/j.ctrv.2015.11.003_b0210","doi-asserted-by":"crossref","first-page":"4708","DOI":"10.1200\/JCO.2007.15.9566","article-title":"Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study","volume":"26","author":"Cohen","year":"2008","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2015.11.003_b0215","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1056\/NEJMoa075853","article-title":"Motesanib diphosphate in progressive differentiated thyroid cancer","volume":"359","author":"Sherman","year":"2008","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.ctrv.2015.11.003_b0220","doi-asserted-by":"crossref","first-page":"5260","DOI":"10.1158\/1078-0432.CCR-10-0994","article-title":"Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation","volume":"16","author":"Carr","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.ctrv.2015.11.003_b0225","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/S1470-2045(10)70203-5","article-title":"Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study","volume":"11","author":"Bible","year":"2010","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.ctrv.2015.11.003_b0230","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/S1470-2045(12)70335-2","article-title":"Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial","volume":"13","author":"Leboulleux","year":"2012","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.ctrv.2015.11.003_b0235","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1089\/thy.2014.0125","article-title":"A phase I study of cabozantinib (XL184) in patients with differentiated thyroid cancer","volume":"24","author":"Cabanillas","year":"2014","journal-title":"Thyroid"},{"issue":"1","key":"10.1016\/j.ctrv.2015.11.003_b0240","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1089\/thy.2014.0123","article-title":"BRAF inhibitor dabrafenib in patients with metastatic BRAF-mutant thyroid cancer","volume":"25","author":"Falchook","year":"2015","journal-title":"Thyroid"},{"issue":"Suppl. 3","key":"10.1016\/j.ctrv.2015.11.003_b0245","article-title":"An open-label, multi-center phase 2 study of the BRAF inhibitor vemurafenib in patients with metastatic or unresectable papillary thyroid cancer (PTC) positive for the BRAF V600 mutation and resistant to radioactive iodine (NCT01286753, No25530)","volume":"49","author":"Brose","year":"2013","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2015.11.003_b0250","doi-asserted-by":"crossref","first-page":"E77","DOI":"10.1210\/jc.2014-2246","article-title":"Efficacy and tolerability of vemurafenib in patients with BRAFV600E-positive papillary thyroid cancer: M.D. Anderson Cancer Center off label experience","volume":"100","author":"Dadu","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"10.1016\/j.ctrv.2015.11.003_b0255","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1056\/NEJMoa1502309","article-title":"Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations","volume":"373","author":"Hyman","year":"2015","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ctrv.2015.11.003_b0260","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1158\/1078-0432.CCR-14-2915","article-title":"Redifferentiation of iodine-refractory BRAF V600E-mutant metastatic papillary thyroid cancer with dabrafenib","volume":"21","author":"Rothenberg","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2015.11.003_b0265","unstructured":"Clinicaltrials.gov. Dabrafenib and lapatinib ditosylate in treating patients with refractory thyroid cancer that cannot be removed by surgery. Available at: <http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01947023>; Accessed November 3, 2015."},{"key":"10.1016\/j.ctrv.2015.11.003_b0270","unstructured":"Clinicaltrials.gov. Dabrafenib with or without trametinib in treating patients with recurrent thyroid cancer. Available at: <http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01723202>; Accessed November 3, 2015."},{"key":"10.1016\/j.ctrv.2015.11.003_b0275","unstructured":"Clinicaltrials.gov. Efficacy and safety of the combination therapy of dabrafenib and trametinib in subjects with BRAF V600E- mutated rare cancers. Available at: <http:\/\/clinicaltrials.gov\/ct2\/show\/NCT02034110>; Accessed November 3, 2015."},{"issue":"1","key":"10.1016\/j.ctrv.2015.11.003_b0280","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.canlet.2013.07.007","article-title":"Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models","volume":"340","author":"Okamoto","year":"2013","journal-title":"Cancer Lett"},{"issue":"17","key":"10.1016\/j.ctrv.2015.11.003_b0285","doi-asserted-by":"crossref","first-page":"5459","DOI":"10.1158\/1078-0432.CCR-07-5270","article-title":"Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase","volume":"14","author":"Matsui","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.ctrv.2015.11.003_b0290","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/ijc.23131","article-title":"E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition","volume":"122","author":"Matsui","year":"2008","journal-title":"Int J Cancer"},{"issue":"23","key":"10.1016\/j.ctrv.2015.11.003_b0295","doi-asserted-by":"crossref","first-page":"7229","DOI":"10.1158\/1078-0432.CCR-09-1980","article-title":"E7080, a multi-tyrosine kinase inhibitor, suppresses the progression of malignant pleural mesothelioma with different proangiogenic cytokine production profiles","volume":"15","author":"Ikuta","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2015.11.003_b0300","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1186\/1471-2407-11-309","article-title":"E7080, a multi-targeted tyrosine kinase inhibitor suppresses tumor cell migration and invasion","volume":"11","author":"Glen","year":"2011","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2015.11.003_b0305","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s10637-014-0181-7","article-title":"Pharmacokinetics and excretion of 14C-lenvatinib in patients with advanced solid tumors or lymphomas","volume":"33","author":"Dubbelman","year":"2015","journal-title":"Invest New Drugs"},{"issue":"8","key":"10.1016\/j.ctrv.2015.11.003_b0310","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1124\/dmd.114.058073","article-title":"Oxidative metabolic pathway of lenvatinib mediated by aldehyde oxidase","volume":"42","author":"Inoue","year":"2014","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"10.1016\/j.ctrv.2015.11.003_b0315","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/cpdd.140","article-title":"Effects of ketoconazole on the pharmacokinetics of lenvatinib (E7080) in healthy participants","volume":"4","author":"Shumaker","year":"2015","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"9","key":"10.1016\/j.ctrv.2015.11.003_b0320","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s40261-014-0217-y","article-title":"Effect of rifampicin on the pharmacokinetics of lenvatinib in healthy adults","volume":"34","author":"Shumaker","year":"2014","journal-title":"Clin Drug Invest"},{"issue":"3","key":"10.1016\/j.ctrv.2015.11.003_b0325","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/jcph.398","article-title":"Influence of hepatic impairment on lenvatinib pharmacokinetics following single-dose oral administration","volume":"55","author":"Shumaker","year":"2015","journal-title":"J Clin Pharmacol"},{"issue":"8","key":"10.1016\/j.ctrv.2015.11.003_b0330","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1158\/1078-0432.CCR-10-2638","article-title":"Phase I dose-escalation study and biomarker analysis of E7080 in patients with advanced solid tumors","volume":"17","author":"Yamada","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.ctrv.2015.11.003_b0335","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1038\/bjc.2012.154","article-title":"A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours","volume":"106","author":"Boss","year":"2012","journal-title":"Br J Cancer"},{"issue":"3","key":"10.1016\/j.ctrv.2015.11.003_b0340","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/bjc.2013.374","article-title":"Phase 1 study of lenvatinib combined with carboplatin and paclitaxel in patients with non-small-cell lung cancer","volume":"109","author":"Nishio","year":"2013","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2015.11.003_b0345","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s00280-013-2339-y","article-title":"A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC)","volume":"73","author":"Molina","year":"2014","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ctrv.2015.11.003_b0350","unstructured":"Clinicaltrials.gov. A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial of lenvatinib (E7080) in 131I-refractory differentiated thyroid cancer. Available at: <http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01321554>; Accessed November 3, 2015."},{"key":"10.1016\/j.ctrv.2015.11.003_b0355","unstructured":"Clinicaltrials.gov. A study of E7080 in subjects with advanced thyroid cancer. Available at: <http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01728623>; Accessed November 3, 2015."},{"key":"10.1016\/j.ctrv.2015.11.003_b0360","unstructured":"Clinicaltrials.gov. Evaluating the safety and efficacy of oral E7080 in medullary and iodine-131refractory, unresectable differentiated thyroid cancers, stratified by histology. Available at: <http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00784303>; Accessed November 3, 2015."},{"issue":"Suppl. 4","key":"10.1016\/j.ctrv.2015.11.003_b0365","article-title":"Phase II study of lenvatinib (LEN), a multi-targeted tyrosine kinase inhibitor, in patients (PTS) with all histologic subtypes of advanced thyroid cancer (differentiated, medullary and anaplastic) [abstract]","volume":"25","author":"Takahashi","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2015.11.003_b0370","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-15-1127","article-title":"A phase 2 trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in advanced medullary thyroid cancer (MTC)","author":"Schlumberger","year":"2015","journal-title":"Clin Cancer Res."},{"issue":"16","key":"10.1016\/j.ctrv.2015.11.003_b0375","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1002\/cncr.29395","article-title":"A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: a clinical outcomes and biomarker assessment","volume":"121","author":"Cabanillas","year":"2015","journal-title":"Cancer"},{"issue":"15","key":"10.1016\/j.ctrv.2015.11.003_b0380","article-title":"Effect of age and lenvatinib treatment on overall survival for patients with 131 I refractory differentiated thyroid cancer in SELECT [abstract]","volume":"33","author":"Brose","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2015.11.003_b0385","unstructured":"Clinicaltrials.gov. A multicenter, open-label, phase 3 trial to compare the efficacy and safety of lenvatinib (E7080) versus sorafenib in first-line treatment of subjects with unresectable hepatocellular carcinoma. Available at: <http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01761266>; Accessed November 3, 2015."},{"key":"10.1016\/j.ctrv.2015.11.003_b0390","unstructured":"Clinicaltrials.gov. Study of E7080 in subjects with advanced endometrial cancer and disease progression. Available at: <http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01111461>; Accessed November 3, 2015."},{"key":"10.1016\/j.ctrv.2015.11.003_b0395","unstructured":"Clinicaltrials.gov. A study of E7080 alone, and in combination with everolimus in subjects with unresectable advanced or metastatic renal cell carcinoma following one prior vascular endothelial growth factor (VEGF)-targeted treatment. Available at: <http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01136733>; Accessed November 3, 2015."},{"key":"10.1016\/j.ctrv.2015.11.003_b0400","unstructured":"Clinicaltrials.gov. Study of the safety and activity of lenvatinib (E7080) in subjects with KIF5B-RET-positive adenocarcinoma of the lung. Available at: <http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01877083?>; Accessed November 3, 2015."},{"key":"10.1016\/j.ctrv.2015.11.003_b0405","unstructured":"Clinicaltrials.gov. E7050 in combination with E7080 in subjects with advanced solid tumors (dose escalation) and in subjects with recurrent glioblastoma or unresectable stage III or stage IV melanoma after prior systemic therapy (expansion cohort and phase 2). Available at: <http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01433991>; Accessed November 3, 2015."},{"issue":"6","key":"10.1016\/j.ctrv.2015.11.003_b0410","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1210\/jc.2013-3588","article-title":"Role of salvage targeted therapy in differentiated thyroid cancer patients who failed first-line sorafenib","volume":"99","author":"Dadu","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.ctrv.2015.11.003_b0415","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1007\/s12020-014-0448-y","article-title":"Second-line sunitinib as a feasible approach for iodine-refractory differentiated thyroid cancer after the failure of first-line sorafenib","volume":"49","author":"Marotta","year":"2015","journal-title":"Endocrine"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737215002017?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737215002017?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,15]],"date-time":"2023-08-15T21:26:34Z","timestamp":1692134794000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737215002017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":83,"alternative-id":["S0305737215002017"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2015.11.003","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2016,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lenvatinib: Role in thyroid cancer and other solid tumors","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2015.11.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}